

Marinomed Expands into Italy and Broadens its Portfolio

03 June 2020 | News

Marinomed extends product pipeline for Marinosolv and Carragelose; Carragelose platform test effectiveness of Carragelose® polymer on SARS-CoV-2 and other respiratory viruses



Marinomed Biotech AG, a globally operating biopharmaceutical company based in Vienna, is entering the Italian market for cold remedies via its Carragelose® products. This market is the third-largest of its kind in Europe. New marketing partner Fidia Farmaceutici Spa is set to offer Carragelose®-based nasal sprays on the Italian market as of autumn 2020. Oral Carragelose® products such as throat sprays and lozenges will also become available to more than 60 million Italians in the following year.

In addition, Marinomed has signed a contract with Sanova Pharma GesmbH, its first distribution partner for Carravin. Carravin offers the combined benefits of a fast-acting decongestant nasal spray with the anti-viral properties of Carragelose®. Its market launch is scheduled for 2021 once the product has obtained bibliographical approval.

Extended Product Pipeline

Besides expanding into new markets, Marinomed is consistently working on the continuous development of its products and platforms, particularly the growth of its product pipeline. "New additions to our pipeline include four Marinosolv® projects for various areas of application in the fields of respiratory and gastrointestinal conditions", says CSO Dr Eva Prieschl-Grassauer.

In terms of the Carragelose® platform, a clinical Phase 1 trial for an inhalation solution as an acute treatment for viral pneumonia is in the preparation stages. "This is to test both the effectiveness of the Carragelose® polymer on SARS-CoV-2 and other viruses of the respiratory tract", explains Eva Prieschl-Grassauer